Citation: Mmb. Seyger et al., THE EFFICACY OF A NEW TOPICAL TREATMENT FOR PSORIASIS - MIRAK, JEADV. Journal of the European Academy of Dermatology and Venereology, 11(1), 1998, pp. 13-18
Authors:
SEYGER MMB
VANDENHOOGEN FHJ
DEBOO T
DEJONG EMGJ
Citation: Mmb. Seyger et al., LOW-DOSE METHOTREXATE IN THE TREATMENT OF WIDESPREAD MORPHEA, Journal of the American Academy of Dermatology, 39(2), 1998, pp. 220-225
Citation: Mmb. Seyger et al., LOCALIZED AND SYSTEMIC SCLERODERMA SHOW DIFFERENT HISTOLOGICAL RESPONSES TO METHOTREXATE THERAPY, Journal of investigative dermatology, 110(4), 1998, pp. 602-602
Citation: Mmb. Seyger et al., DECREASED STAINING OF HEPARAN-SULFATE IN NON-LESIONAL SKIN OF A SUBGROUP OF PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS, Acta dermato-venereologica, 78(5), 1998, pp. 326-330
Citation: Mmb. Seyger et al., EPICUTANEOUS APPLICATION OF LEUKOTRIENE B-4 INDUCES PATTERNS OF TENASCIN AND A HEPARAN-SULFATE PROTEOGLYCAN EPITOPE THAT ARE TYPICAL FOR PSORIATIC LESIONS, Archives of dermatological research, 289(6), 1997, pp. 331-336
Authors:
SEYGER MMB
VANDENHOOGEN FHJ
DEBOO T
DEJONG EMGJ
Citation: Mmb. Seyger et al., RELIABILITY OF 2 METHODS TO ASSESS MORPHEA - SKIN SCORING AND THE USEOF A DUROMETER, Journal of the American Academy of Dermatology, 37(5), 1997, pp. 793-796
Citation: Mmb. Seyger et al., DECREASED STAINING OF HEPARAN-SULFATE PROTEOGLYCANS IN NON LESIONAL SKIN OF A SUBGROUP OF SLE PATIENTS, Journal of investigative dermatology, 109(3), 1997, pp. 421-421
Authors:
SEYGER MMB
RITTERBACH J
CREUTZIG U
GNEKOW AK
GOBEL U
GRAF N
REITER A
LAMPERT F
HARBOTT J
Citation: Mmb. Seyger et al., 12Q13, A NEW RECURRENT BREAKPOINT IN ACUTE NONLYMPHOBLASTIC LEUKEMIA, Cancer genetics and cytogenetics, 80(1), 1995, pp. 23-28
Citation: Emgl. Dejong et al., EXPRESSION OF HEPARANSULPHATE PROTEOGLYCANS IN PSORIASIS, Journal of investigative dermatology, 105(3), 1995, pp. 465-465